Vir Biotechnology
Vir Biotechnology raises $250M Series E at $3.3B valuation
Vir Biotechnology: Series E Funding Round
Vir Biotechnology has successfully raised $250M in Series E funding, reaching a valuation of $3.3B.
Company Overview
Infectious disease treatment development
Funding Details
The Series E round was led by SoftBank Vision Fund, with participation from Arch Venture Partners, ARCH Venture Partners, Intermediate Capital Group.
Company Information
- Headquarters: 499 Illinois Street, San Francisco, CA 94158
- Founded: 2016
- Employees: 500+
- Category: Biotech
Investment
Vir Biotechnology plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- SoftBank Vision Fund: Verified investor in Series E
- Arch Venture Partners: Verified investor in Series E
- ARCH Venture Partners: Verified investor in Series E
- Intermediate Capital Group: Verified investor in Series E
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started